Maxillofacial Plastic and Reconstructive Surgery

  • Volume 41
  • /
  • Pages.38.1-38.13
  • /
  • 2019
  • /
  • 2288-8101(pISSN)
  • /
  • 2288-8586(eISSN)
Korean Association of Maxillofacial Plastic and Reconstructive Surgeons (대한악안면성형재건외과학회)
권호 표지
DOI QR코드

DOI QR Code

Application of botulinum toxin in maxillofacial field: part I. Bruxism and square jaw

  • Kwon, Kyung-Hwan (Department of Oral and Maxillofacial Surgery, College of Dentistry, Wonkwang University) ;
  • Shin, Kyung Su (Department of Oral and Maxillofacial Surgery, College of Dentistry, Wonkwang University) ;
  • Yeon, Sung Hee (Department of Oral and Maxillofacial Surgery, College of Dentistry, Wonkwang University) ;
  • Kwon, Dae Gun (Department of Oral and Maxillofacial Surgery, College of Dentistry, Wonkwang University)
  • Received : 2019.06.14
  • Accepted : 2019.08.16
  • Published : 2019.12.31
Download PDF
⟨ Previous Next ⟩

Abstract

The application of botulinum in oral and maxillofacial surgery begins in 1982, where Jan Carruthers started using it for reducing the muscle mass and smoothing the skin, and since then it has been used for cosmetic purposes. In Korea, it is already being used by various specialties including dentistry (oral and maxillofacial surgery, oral medicine), plastic surgery, dermatology, ophthalmology, general surgery, and orthopedic surgery, etc. Each specialty approaches to Botox with its own medical indications. In this article, we will discuss the maxillofacial application of botulinum toxin, which includes theoretical and practical aspects of such as bruxism and square jaw.

Keywords

References

  1. Scott AB (1980) Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. Ophthalmology 87:1044-1049 https://doi.org/10.1016/S0161-6420(80)35127-0
  2. Selter PE (2002) Therapeutic use of botulinum toxins: Background and History. Clin J Pain 18:119-124
  3. Simpson LL (2000) Identification of the characteristics that underlie botulinum toxin potency: implications for designing novel drugs. Biochemie 82:943-953 https://doi.org/10.1016/S0300-9084(00)01169-X
  4. Freud B, Schwartz M, Symington J (1999) The use of botulinum toxin for the treatment of temporomandibular disorders: Preliminary findings. J Oral Maxillofac Surg 57:916-920 https://doi.org/10.1016/S0278-2391(99)90007-1
  5. Lu DW, Lippitz J (2009) Complications of botulinum neurotoxin. Dis Mon. 55:198-211 https://doi.org/10.1016/j.disamonth.2009.01.001
  6. Popoff MR, Bouvet P (2013) Genetic characteristics of toxigenic Clostridia and toxin gene evolution. Toxicon 75:63-89 https://doi.org/10.1016/j.toxicon.2013.05.003
  7. Van Zndiijcke M, Marchau MM (1990) Treatment of bruxism with botulinum toxin injections. J Neurol Neurosurg Psychiatry 1990;53:530. https://doi.org/10.1136/jnnp.53.6.530
  8. Smyth AG (1994) Botulinum toxin treatment of bilateral masseteric hypertrophy. Br. J. Oral Maxillofacial Surg 32:29-33 https://doi.org/10.1016/0266-4356(94)90169-4
  9. Kim SY, Kim YK, Yun PY, Bae JH (2018) Treatment of non-odontogenic orofacial pain using botulinum toxin-A: a retrospective case series study. Dig Maxillofac Plast Reconstr Surg. https://doi.org/10.1186/s40902-018-0159-z
  10. Archana MS (2016) Toxin yet not toxic: botulinum toxin in dentistry. Saudi Dent J 28:63-69 https://doi.org/10.1016/j.sdentj.2015.08.002
  11. Kwon TG (2016) Botulinum toxin related research in maxillofacial plastic and reconstructive surgery. Dig Maxillofac Plast Reconstr Surg. https://doi.org/10.1186/s40902-016-0080-2
  12. Carruthers J, Carruthers A. (1991) Botulinum toxin use on Glabells wrinkles. Presented at the annual meeting of the American Society for dermatologic surgery Orlando florida. 13-17 March. 1991
  13. Carruthers JD, Carruthers JA (1992) Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 18:17-21 https://doi.org/10.1111/j.1524-4725.1992.tb03295.x
  14. To EW, Ahuja AT, Ho WS, King WW, Wong WK, Pang PC, Hui AC (2001) A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement. Br J Plat Surg 54:197-200 https://doi.org/10.1054/bjps.2000.3526
  15. Sano K, Ninomiya H, Ckine J, Michael B, Pe MB, Inokuchi T (1991) Application of magnetic resonance imaging and ultrasonography to preoperative evaluation of masseteric hypertrophy. J Craniomaxillofac Surg 19:223-226 https://doi.org/10.1016/S1010-5182(05)80552-9
  16. Loder E, Biondi D (2002) Use of botulinum toxins for chronic headaches: A focused review. The Clin J Pain 18:169-176
  17. Pidcock FS, Wise JM, Christensen JR (2002) Treatment of severe posttraumatic bruxism with botulinum toxin-A: Case Report. J Oral Maxillofac Surg 60:115-117 https://doi.org/10.1053/joms.2002.29127
  18. Ivanhoe CB, Lai JM, Francisco GE (1997) Bruxism after brain injury: Successful treatment with Botulinum toxin-A. Arch Phys Med Rehabil 78:1272-1273 https://doi.org/10.1016/S0003-9993(97)90343-9
  19. Freund B, Schwartz M, Symington JM (1999) The use of botulinum toxin for the treatment of temporomandibular disorders: preliminary findings. J Oral Maxillofac Surg 57:916-920 https://doi.org/10.1016/S0278-2391(99)90007-1
  20. Niamtu J 3rd (2003) Botulinum toxin A: a review of 1,085 oral and maxillofacial patient treatments. J Oral Maxillofac Surg 61:317-324. https://doi.org/10.1053/joms.2003.50069
  21. Attanasio R (1997) An overview of bruxism and its management. Dent Clin North Am 41:229-241
  22. Pratap-Chand R, Gourie-Devi M (1985) Bruxism: its significance in coma. Clin Neurol Neurosurg 87:113-117 https://doi.org/10.1016/0303-8467(85)90107-6

Cited by

  1. Efficacy and Safety of Botulinum Toxin vs. Placebo in Depression: A Systematic Review and Meta-Analysis of Randomized Controlled Trials vol.11, 2020, https://doi.org/10.3389/fpsyt.2020.603087